Drug: JNJ-42160443: chronic pain clinical trials
Registry records that list "Drug: JNJ-42160443" as an intervention. Being studied does not mean an intervention works or is approved.
8
Trials with Canadian sites
0
Recruiting in Canada
10
Registry records in total
Trials in Canada
8 trials, 0 recruiting or not yet recruiting. Recruiting first.
| Phase | Provinces | ||||
|---|---|---|---|---|---|
| A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis NCT01094262 | Terminated | Phase 2 | Ontario, Quebec | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2010-04-20 |
| A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis NCT01094262 | Terminated | Phase 2 | Ontario, Quebec | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2010-04-20 |
| A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain NCT01060254 | Terminated | Phase 2 | Ontario | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2010-04-06 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain NCT00973141 | Terminated | Phase 2 | British Columbia, Newfoundland and Labrador, Ontario, Quebec | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-09-16 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain NCT00973141 | Terminated | Phase 2 | British Columbia, Newfoundland and Labrador, Ontario, Quebec | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-09-16 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain NCT00973141 | Terminated | Phase 2 | British Columbia, Newfoundland and Labrador, Ontario, Quebec | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-09-16 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain NCT00973141 | Terminated | Phase 2 | British Columbia, Newfoundland and Labrador, Ontario, Quebec | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-09-16 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain NCT00973141 | Terminated | Phase 2 | British Columbia, Newfoundland and Labrador, Ontario, Quebec | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-09-16 |
Trials worldwide (outside Canada)
2 trials, 0 recruiting or not yet recruiting. Recruiting first.
| Phase | Countries | ||||
|---|---|---|---|---|---|
| A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain NCT00929188 | Completed | Phase 2 | France, Poland, Portugal, Spain and 1 more | Janssen Research & Development, LLC | 2009-10 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) NCT00964990 | Terminated | Phase 2 | Belgium, Netherlands, Spain, United States | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-09 |
Conditions studied with this intervention
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status.